Please upgrade your browser.
An intravenous bisphosphonate, Zometa(R) is the only therapy to demonstrate efficacy in reducing or delaying bone complications across a broad range of tumour types such as breast, prostate, lung and renal cell cancers.
Van Andel Institute (VAI) researchers have identified unique DNA changes in each of several types of renal cell carcinoma (RCC), the most common form of kidney cancer in adults. These findings could aid in the diagnosis of these cancers since the many types of RCC are currently identified only by their appearance.
Despite these horror stories, Congress is trying to create a similar agency right here in the United States.
Pfizer announced that important study results involving the company's leading anticancer agent, Sutent (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12-16 September 2008.
AGS-003 to be tested in combination with sunitinib.
Earn $150 for participation.
The spiralling cost of drugs presents an unavoidable challenge.
The rumor seems to be going around that Pfizer (PFE) might be making a bid for Bayer (aka Bayer/Schering). That sounds ridiculous to me, and if Pfizer actually does such a thing, its management is even more starved for ideas than its nastiest critics could believe.
Novartis said on Tuesday that RAD001 or everolimus, which it plans to sell under the brand name Afinitor, had been accepted for fast review given the medicine's potential to help patients who fail to respond to standard therapy.
"The NHS is going to face meltdown just because of one disease, so we're going to have to re-structure things for the future, look at new ways of bringing money into the health service and that is a huge political challenge."
|NeonCRM by Neon One|